Form 4: Sangamo Therapeutics Director Acquires Shares and Options

Director H Stewart Parker acquired 25,000 shares of common stock and options to purchase 50,000 shares of Sangamo Therapeutics.

Summary

• On June 4, 2024, H Stewart Parker, a director of Sangamo Therapeutics, acquired 25,000 shares of common stock.
• These shares were obtained through the settlement of a restricted stock unit (RSU) grant.
• The RSU will fully vest on the earlier of June 4, 2025, or the day prior to the 2025 annual meeting of stockholders, contingent upon continuous service.
• Parker also acquired options to purchase 50,000 shares of common stock at an exercise price of $0.5676.
• The options are immediately exercisable, but unvested shares are subject to repurchase rights by the issuer.
• The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, contingent upon continuous service.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects standard insider transactions. The acquisition of shares and options could be seen as a positive sign, but it's a routine filing.

Positives

• The director's acquisition of shares and options may signal confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. These transactions can be viewed as a signal of management's confidence in the company's prospects, but should be considered in the context of the individual's overall holdings and trading history.

Stakeholder Impact

• Shareholders may view the director's acquisition of shares and options as a positive signal.

Key Dates